Skip to main content
. 2019 Feb 26;92(1096):20180792. doi: 10.1259/bjr.20180792

Figure 3.

Figure 3.

Frequency of patients with an SUVmax increase by >30% when using BSREM instead of OSEM. We observed the tumor SUVmax to increase by >30% most often in patients with adenocarcinoma, when using BSREM with lower β-values, and when comparing BSREM with OSEMTOF (A). This was less frequent when comparing BSREM with OSEMPSF (B).